Navigating Thrombotic Risks in Sex Hormone Therapy

Sex hormone therapy serves many clinical purposes today, including contraception and menopause management. However, clinicians must address the risk of hormone-associated venous thromboembolism carefully. This complication arises from complex changes in the coagulation cascade. Therefore, choosing the right treatment route is crucial for patient safety. Understanding individual backgrounds helps minimize these life-threatening events effectively.

Managing Hormone-Associated Venous Thromboembolism Risks

Different delivery methods significantly alter the risk of developing blood clots. For instance, oral estrogens increase the production of procoagulant factors in the liver. In contrast, transdermal patches bypass this first-pass metabolism effectively. Consequently, transdermal therapy carries a much lower risk for most patients. Furthermore, personal history and inherited genetics also play a major role in overall danger. Doctors should evaluate every patient’s specific risk profile before starting any treatment regimen.

Practical Guidance for Clinical Care

Managing patients during surgical procedures requires a highly personalized strategy. Many surgeons suggest pausing therapy to prevent postoperative clots. Nevertheless, some evidence supports continuing treatment alongside standard pharmacological prophylaxis. Additionally, lifestyle factors like obesity and smoking further elevate the baseline risk levels. Thus, you must weigh these clinical factors during the initial consultation. Always prioritize shared decision-making to achieve the best health outcomes for your patients.

Frequently Asked Questions

Q1: Which hormone therapy route has the lowest risk of clots?

Transdermal formulations typically carry the lowest risk of hormone-associated venous thromboembolism. This is because they avoid the liver’s first-pass effect, which otherwise triggers procoagulant factor production.

Q2: Should patients stop hormone therapy before undergoing surgery?

Clinicians often individualize this decision based on the specific surgery and patient risk. While some doctors pause therapy, others continue it with the support of standard clot prevention measures like anticoagulants.

Q3: Does the risk of thrombosis decrease over time?

Evidence suggests that the risk is often highest during the first year of therapy. After this period, the risk may stabilize, though it often remains higher than the risk in non-users.

References

Skeith L et al. Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk. N Engl J Med. 2026 Apr 16. doi: 10.1056/NEJMra2202438. PMID: 41985134.
Hicks A et al. Safety of menopause hormone therapy in postmenopausal women at higher risk of venous thromboembolism: a systematic review. Climacteric. 2025.
Shatzel J et al. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Res Pract Thromb Haemost. 2022.